Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSIBBBOOST
NL-OMON59758Phase 2Not yet recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib and febuxostat in non-small cell lung cancer (NSCLC), sponsored by Maastricht University Medical Center+. Primary endpoint: Osimertinib CSF to plasma concentration ratio. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
osimertinibfebuxostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59758.